Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial

被引：0

作者：

Mease, P

Gladman, D

Ritchlin, C

Weinberg, M

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Univ Rochester, Sch Med & Dent, Rochester, NY USA

[4] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

下载

页码：AB214 / AB214

页数：1

共 50 条

[21] Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset
Imagawa, T.
Ozawa, R.
Miyamae, T.
Mori, M.
Nerome, Y.
Imanaka, H.
Takei, S.
Kawano, Y.
Iwata, N.
Miyoshi, M.
Murata, T.
Nishimoto, N.
Kishimoto, T.
Yokota, S.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 550 - 550
[22] Long-term clinical trial safety experience with adalimumab 40 mg every other week for treatment of moderate to severe psoriasis
Tyring, Stephen
Frankel, Ellen
Rozzo, Stephen
Gu, Yihua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB131 - AB131
[23] Updated pooled clinical trial safety experience with adalimumab for treatment of patients with moderate to severe psoriasis
Tyring, Stephen
Frankel, Ellen
Okun, Martin
Gu, Yihua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB174 - AB174
[24] Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa The SHARPS Randomized Clinical Trial
Bechara, Falk G.
Podda, Maurizio
Prens, Errol P.
Horvath, Barbara
Giamarellos-Bourboulis, Evangelos J.
Alavi, Afsaneh
Szepietowski, Jacek C.
Kirby, Joslyn
Geng, Ziqian
Jean, Christine
Jemec, Gregor B. E.
Zouboulis, Christos C.
JAMA SURGERY, 2021, 156 (11) : 1001 - 1009
[25] Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Panaccione, Remo
Loftus, Edward V., Jr.
Binion, David
McHugh, Kevin
Alam, Shamsul
Chen, Naijun
Guerette, Benoit
Mulani, Parvez
Chao, Jingdong
CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (08): : 419 - 425
[26] Efficacy and safety of 6-month depot leuprolide acetate for the treatment of prostate cancer: Results of a 48-week study
Young, J.
Spitz, A.
Larsen, L.
Mattia-Goldberg, C.
Donnelly, J.
Chwalisz, K.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-na?ve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
Reich, Kristian
Kristensen, Lars Erik
Smith, Saxon D.
Rich, Phoebe
Sapin, Christophe
Leage, Soyi Liu
McKenzie, Robert
Schuster, Christopher
Riedl, Elisabeth
Gooderham, Melinda
DERMATOLOGY PRACTICAL & CONCEPTUAL, 2022, 12 (02):
[28] Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
Pelechas, Eleftherios
Voulgari, Paraskevi V.
Drosos, Alexandros A.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1073 - 1079
[29] Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial
Kimball, Alexa
Zhong, Jianhua
Valdes, Joaquin
Gordon, Kenneth
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : AB168 - AB168
[30] Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents: PIANO 48-week results
Tudor-Williams, G.
Cahn, P.
Chokephaibulkit, K.
Fourie, J.
Karatzios, C.
Dincq, S.
Kakuda, T. N.
Nijs, S.
Tambuyzer, L.
Tomaka, F.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 66 - 66

← 1 2 3 4 5 →